Heart Failure
Conditions
Interventions
The hypertension treatment group was given injectable YQFM (freeze-dried) treatment on the basis of conventional Western medical treatment.:On the basis of the standard treatment in the YQFM group, YQ
The hypopiesis treatment group was given injectable YQFM (freeze-dried) treatment on the basis of conventional Western medical treatment.:On the basis of the standard treatment in the YQFM group, YQFM
The hypertension control group was given conventional Western medical treatment.:None
The hypopiesis control group was given conventional Western medical treatment.:None
Sponsors
The Second Hospital of Jilin University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Age 18-75 years old; 2. According to the 2024 Chinese Guidelines for the diagnosis and treatment of heart failure, the patients were diagnosed with HFrEF, HFimpEF, and HFmrEF, and met the TCM syndrome criteria; 3. concurrent hypertension (HP>=140/90 MMHG according to the 2023ESH Guidelines for the management of hypertension) or hypotension (systolic blood pressure < 90mmHg within 72 hours and maintained between 90 and 110mmHg for more than 12 hours after treatment with vasoactive drugs); 4. The subjects voluntarily participated and signed the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Have a history of allergy to any component of Yiqifumai; (2) patients with severe liver and kidney dysfunction (eGFR<=30ml/min/1.73m^2 or active nephropathy, serum aminotransferase or bilirubin =3 times the upper limit of the clinical reference value), other serious primary or mental diseases affecting life span or malignant tumors; 3. Patients with pregnancy, preparation or suspected pregnancy, abortion, lactation or delivery in the past 6 months; 4. Participating in other clinical investigators; 5. Using other traditional Chinese medicine at the same time; 6. Patients with severe hypotensive shock; 7. Investigators deemed it inappropriate for participants.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement of cardiac function; | — |
Secondary
| Measure | Time frame |
|---|---|
| NT-proBNP level;Blood pressure changes before and after treatment; | — |
Countries
China
Contacts
Public ContactWang Junnan
The Second Hospital of Jilin University
Outcome results
None listed